Elixiron Immunotherapeutics
Taipei
About Elixiron Immunotherapeutics
Elixiron Immunotherapeutics is driven by an international team with a shared vision to produce next-generation immunotherapies. This vision drives our mission to target rare and inflammatory disorders as well as cancer for indications that could substantially benefit from advances in immunotherapy approaches. We employ advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics derived from a proprietary human antibody domain phage display library and a single human B cell antibody cloning platform to develop innovative therapies. Our two lead pipeline candidates are in phase 1 clinical trials. EI-1071, a small molecule inhibitor of CSF-1R kinase activity, is being explored as a potential therapy for Alzheimer's disease as well as tenosynovial giant cell tumors, and a monoclonal antibody, EI-001 is being developed for the treatment of vitiligo and other immunological disorders.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $14.8M
- Funding stage: Early Stage Venture
- Last round: Series B (Jun 2025)
- Website: elixiron.com
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/elixiron-immunotherapeutics-108896 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.